Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The purpose of this study is to determine if an investigational treatment is effective
compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial
conjunctivitis.
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Cornea
Enrollment Eligibility
Inclusion Criteria:
- An understanding, ability, and willingness to fully comply with study procedures and
restrictions (by the parent(s), guardian, or legally authorized representative, if
applicable).
- Ability to voluntarily provide written, signed, and dated (personally or via a
parent(s), guardian, or legally authorized representative(s) informed consent (and
assent, if applicable) to participate in the study.
- Participants of any age at Visit 1 (Note: participants less than (<) 3 months of age
at Visit 1 must have been full-term, that is (ie,) greater than or equal to (>=) 37
weeks gestational age at birth).
- Have a negative AdenoPlus® test in both eyes within 24 hours of Visit 1 or at Visit 1.
- Have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye
confirmed by the presence of the following minimal clinical signs and symptoms in that
same eye:
1. Report presence of signs and/or symptoms of bacterial conjunctivitis for less
than or equal to (<=) 4 days prior to Visit 1
2. Bulbar conjunctival injection: a grade of >= 1 on 0-4 scale of Bulbar
Conjunctival Injection Scale
3. Ocular conjunctival discharge: a grade of >= 1 (mild) on a 0-3 scale of Ocular
Conjunctival Discharge Scale
- Be willing to discontinue contact lens wear for the duration of the study.
- Have a Best Corrected Visual Acuity (BCVA) of 0.60 logMAR or better in each eye as
measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA will
be assessed by an age appropriate method in accordance with the AAP Policy Statement
for Visual System Assessment in Infants, Children, and Young Adults by Pediatricians
(Donahue and Baker, 2016; American Academy of Pediatrics, 2016). The policy statement
recommends formal vision screening can begin at 3 years of age. VA measurements for
children under the age of 3 will be done at the discretion of the investigator. If not
done, child should be able to fixate on and follow a moving object, except
participants < 2 months of age who have not yet developed this ability. Participants <
2 months will be enrolled at the discretion of investigator.
- Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
contraceptive requirements of the protocol or females of non-childbearing potential.
Exclusion Criteria:
- Current or recurrent disease that could affect the action, absorption, or disposition
of the investigational product, or clinical or laboratory assessments, per
investigator's discretion.
- Current or relevant history of physical or psychiatric illness, any medical disorder
that may make the participant unlikely to fully complete the study, or any condition
that presents undue risk from the investigational product or procedures.
- Have known or suspected intolerance or hypersensitivity to the investigational
product, closely related compounds, or any of the stated ingredients.
- Prior enrollment in a FST-100 or SHP640 clinical study.
- Participants who are employees, or immediate family members of employees (who are
directly related to study conduct), at the investigational site.
- Have a history of ocular surgical intervention within <= 6 months prior to Visit 1 or
planned for the period of the study.
- Have a preplanned overnight hospitalization during the period of the study.
- Have presence of any intraocular, corneal, or conjunctival ocular inflammation
(example [eg,] uveitis, iritis, ulcerative keratitis, chronic blepharoconjunctivitis),
other than bacterial conjunctivitis.
- Have active or a history of ocular herpes.
- Have at enrollment or within <= 30 days of Visit 1, a clinical presentation more
consistent with the diagnosis of non-infectious conjunctivitis (except presumed
seasonal/perennial allergic conjunctivitis) or non-bacterial ocular infection (eg,
viral, fungal, acanthamoebal, or other parasitic). Note: history or concomitant
presence of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is
not exclusionary.
- Neonates or infants (ie, participants less than 12 months of age) who have suspected
or confirmed (based on the result of any test conducted prior to screening)
conjunctivitis of gonococcal, chlamydial, herpetic or chemical origin.
- Neonates or infants (ie, participants less than 12 months of age) whose birth mothers
had any sexually transmitted disease within 1 month of delivery or any history of
genital herpes.
- Presence of nasolacrimal duct obstruction at Visit 1 (Day 1).
- Presence of any significant ophthalmic condition (eg, Retinopathy of Prematurity,
congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic
involvement that could affect study variables.
- Be a known intraocular pressure (IOP) steroid responder, have a known history or
current diagnosis of glaucoma or be a glaucoma suspect.
- Have any known clinically significant optic nerve defects.
- Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary
to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect
or any significant corneal opacity at Visit 1.
- Presence of significant, active condition in the posterior segment that requires
invasive treatment (eg, intravitreal treatment with vascular endothelial growth factor
inhibitors or corticosteroids) and may progress during the study participation period.
- Have used any topical ocular or systemic antibiotics within <= 7 days of enrollment.
- Have used any topical ocular non-steroidal anti-inflammatory drugs within <= 1 day of
enrollment.
- Have used any topical ophthalmic steroids in the last <= 14 days.
- Have used any systemic corticosteroid agents within <= 14 days of Day 1. Stable
(initiated >= 30 days prior to enrollment) use of inhaled and nasal corticosteroids is
allowed, given no anticipated change in dose for the duration of the study. Topical
dermal steroids are allowed except in the periocular area.
- Have used non-corticosteroid immunosuppressive agents within <= 14 days of Day 1.
- Have used any topical ophthalmic products, including tear substitutes, and
over-the-counter preparations such as lid scrubs, within 2 hours of Visit 1 and be
unable to discontinue all topical ophthalmic products for the duration of the study.
Use of hot or cold compresses is also not permitted during the study.
- Have any significant ocular disease (eg, Sjogren's syndrome) or any uncontrolled
systemic disease or debilitating disease (eg, cardiovascular disease, hypertension,
sexually transmitted diseases/infections, diabetes, or cystic fibrosis) that may
affect the study parameters, per investigator's discretion.
- Any known history of immunodeficiency disorder or known active conditions predisposing
to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence
of active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone
marrow transplantation.
- Within 30 days prior to the first dose of investigational product:
1. Have used an investigational product or device, or
2. Have been enrolled in a clinical study (including vaccine studies) that, in the
investigator's opinion, may impact this Shire-sponsored study.